GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Forward PE Ratio

Procaps Group (Procaps Group) Forward PE Ratio : 18.15 (As of Jun. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Forward PE Ratio?

Procaps Group's Forward PE Ratio for today is 18.15.

Procaps Group's PE Ratio without NRI for today is 86.67.

Procaps Group's PE Ratio for today is 5.00.


Procaps Group Forward PE Ratio Historical Data

The historical data trend for Procaps Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Forward PE Ratio Chart

Procaps Group Annual Data
Trend 2022-12 2023-12 2024-05
Forward PE Ratio
10.95 20.16 16.00

Procaps Group Quarterly Data
2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 15.36 10.45 10.95 90.09 13.87 18.12 20.16 17.06

Competitive Comparison of Procaps Group's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Procaps Group's Forward PE Ratio falls into.



Procaps Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Procaps Group  (NAS:PROC) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Procaps Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Procaps Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371